<DOC>
	<DOCNO>NCT01149291</DOCNO>
	<brief_summary>The aim post-marketing observational study obtain data long term use , safety efficacy selective Vitamin D Receptor Activator 's prescribe normal clinical set accord approve Summary Product Characteristics treatment secondary hyperparathyroidism hemodialysis patient Turkey . The relation safety data PTH ( Parathyroid hormone ) suppression time evaluate . Also number incidence hypercalcemia hyperphosphatemia record .</brief_summary>
	<brief_title>A Study Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis , Receiving Selective Vitamin D Receptor Activator 's Prevention Treatment Secondary Hyperparathyroidism</brief_title>
	<detailed_description>The scientific purpose study obtain data use sVDRA ( Selective Vitamin D Receptor Activator ) real-life clinical practice . This study allow u observe drug effectiveness distinct geography . Treatment effect , well maintenance result record 18 month period order obtain experience long term use sVDRA ( Selective Vitamin D Receptor Activator ) . Furthermore center , additional blood parameter , hsCRP ( high sensitivity C-reactive protein ) , examine part clinical routine . The primary aim study : - To assess percentage change iPTH ( intact parathyroid hormone ) level monthly among hemodialysis patient sHPT ( secondary hyperparathyroidism ) receive sVDRA ( Selective Vitamin D Receptor Activator ) therapy . Secondary aim : - To observe change commonly assess biochemical parameter bone mineral metabolism ( Ca ( Calcium ) , P ( Phosphorus ) , ALP ( Alkaline phosphatase ) additionally hsCRP ( high sensitivity C-reactive protein ) cardiovascular inflammatory marker . - To evaluate routinely checked parameter like albumin , hemoglobin dialysis adequacy ( KT/V ) . - To collect evaluate data adverse event order establish safety profile sVDRA ( Selective Vitamin D Receptor Activator ) daily clinical practice . - To collect mortality data 6 month 12 month observational period 6 month drop . Patients follow 12 month within post-marketing observational study check mortality data 6 month follow period . The enrollment period exceed 6 month . All demographic information summarize use descriptive statistic graph . Laboratory level assess use mean , median , minimum , maximum , standard deviation percentage visit basis . The mean difference laboratory level visit also summarize graphic assess use percentage . Alkaline phosphatase hsCRP ( high sensitivity C-reactive protein ) level also summarize use descriptive statistic graph per visit . sVDRA ( Selective Vitamin D Receptor Activator ) dose change per visit summarize descriptive statistic graph . Mortality analyze life table . By take account primary secondary aim study , able achieve therapeutic success iPTH ( intact parathyroid hormone ) level change sVDRA ( Selective Vitamin D Receptor Activator ) treatment perform mortality assessment follow 6 month collect data regard safety efficacy sVDRAs ( Selective Vitamin D Receptor Activators ) long term use , determine enroll totally 510 patient 30 site .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<criteria>Patients secondary hyperparathyroidism presence chronic kidney disease stage 5 receive hemodialysis treat sVDRA 's ( Selective Vitamin D Receptor Activator ) injection iPTH ( intact parathyroid hormone ) &gt; 300pg/ml , correct serum Ca ( Calcium ) &lt; 10.2 mg/dl , serum P ( Phosphorus ) &lt; 6 mg/dl Male female ( pregnant planning pregnant next 12 month ) patient equal old 18 year age Signed Informed consent subject Hypertensive Diabetic subject must optimal steady medication regimen 30 day Subject know hypersensitivity and/or toxicity vitamin D metabolites and/or product ingredient Subject participate clinical study within last month If sVDRA 's ( Selective Vitamin D Receptor Activator ) contraindicate accord SmPC ( Summary Product Characteristics )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>high sensitivity C-reactive protein ( hsCRP )</keyword>
	<keyword>cardiorenal</keyword>
	<keyword>end stage renal disease ( ESRD )</keyword>
	<keyword>Secondary hyperparathyroidism ( SHPT )</keyword>
	<keyword>dialysis</keyword>
	<keyword>paricalcitol</keyword>
	<keyword>osteodystrophy</keyword>
	<keyword>selective Vitamin D receptor activator ( sVDRA )</keyword>
	<keyword>chronic kidney disease</keyword>
</DOC>